TTAC is experiencing heavy censorship on many social media channels since we’ve been targeted by the mainstream media sellouts, social media bullies, and political turncoats. Be sure to get the TRUTH by subscribing to our email list. It’s free.
In June 2021, the US Food and Drug Administration (FDA) approved a new drug, Aduhelm, developed by Biogen to treat Alzheimer’s disease. The approval was based on data from clinical trials that showed Aduhelm to be effective in reducing beta-amyloid plaques in the brain, which are a hallmark of Alzheimer’s disease. However, the approval was controversial and met with a lot of criticism, as there were concerns about the drug’s efficacy and safety, as well as the FDA’s decision-making process.
Now, several months later, the controversy surrounding Aduhelm is still ongoing, with a congressional investigation being launched into the FDA’s approval of the drug. This investigation comes amid concerns about the long history of malfeasance and inappropriate relationships between the FDA and the pharmaceutical industry.
The FDA is responsible for regulating the pharmaceutical industry and ensuring that drugs are safe and effective before they are approved for use. However, there have been numerous instances where the FDA has failed to do so, either by approving drugs that later turned out to be harmful or by approving drugs that were not actually effective.
One example of this is the case of Vioxx, a painkiller that was approved by the FDA in 1999. Vioxx was widely prescribed for years, but it was later found to increase the risk of heart attacks and strokes, and it was eventually pulled from the market in 2004. The FDA was criticized for not taking action sooner to remove the drug from the market, and it was later revealed that there were concerns about the drug’s safety that were ignored by the FDA.
Another example is the case of Avandia, a diabetes drug that was approved by the FDA in 1999. Avandia was later found to increase the risk of heart attacks and was eventually restricted in its use by the FDA. Again, the FDA was criticized for not taking action sooner to address the safety concerns surrounding the drug.
These are just two examples of drugs that were approved by the FDA despite safety concerns. There are many more examples, and they all point to a larger problem with the FDA’s relationship with the pharmaceutical industry. There are concerns that the FDA is too closely aligned with the pharmaceutical industry and that this relationship has compromised the FDA’s ability to regulate the industry effectively.
One of the ways in which the pharmaceutical industry exerts influence over the FDA is through the process of drug approval. Pharmaceutical companies are required to submit data from clinical trials to the FDA in order to get their drugs approved. However, there are concerns that pharmaceutical companies manipulate this data in order to make their drugs look more effective than they actually are.
In the case of Aduhelm, there are concerns that the data from the clinical trials was manipulated in order to make the drug look more effective than it actually is. The clinical trials for Aduhelm were initially discontinued because they did not show significant improvement in patients with Alzheimer’s disease. However, the trials were later resumed and the data was reanalyzed, leading to the FDA’s approval of the drug.
There are also concerns about the safety of Aduhelm. The drug is expensive, with an annual cost of $56,000 per patient, and there are concerns that it could lead to serious side effects, such as brain swelling and bleeding. Despite these concerns, the FDA approved the drug, and it is now being prescribed to patients with Alzheimer’s disease.
The controversy surrounding Aduhelm has led to a congressional investigation into the FDA’s approval process. The investigation will look into the relationship between the FDA and Biogen, the pharmaceutical company that developed Aduhelm, as well as the FDA’s decision-making process when it comes to approving drugs.
This investigation is long overdue. There have been concerns about the FDA’s relationship with the pharmaceutical industry for many years, and it is important that these concerns are addressed in order to ensure that the FDA is able to regulate the industry effectively and ensure that drugs are safe and effective for patients.
One of the reasons why there is so much concern about the FDA’s relationship with the pharmaceutical industry is because of the revolving door between the two. Many FDA officials go on to work for pharmaceutical companies after they leave the agency, and many pharmaceutical executives go on to work for the FDA. This creates a conflict of interest and raises questions about whether the FDA is truly independent from the industry it is supposed to regulate.
Another issue is the funding of the FDA. The FDA is primarily funded by user fees paid by the pharmaceutical industry. This means that the FDA is reliant on the industry for its funding, which could compromise its ability to regulate the industry effectively. There are concerns that the FDA is too dependent on the industry for its funding and that this has led to a cozy relationship between the two.
The FDA has acknowledged these concerns and has taken steps to address them. In 2018, the FDA announced a new policy to increase transparency around the relationship between the agency and the pharmaceutical industry. The policy requires the disclosure of any financial conflicts of interest that could influence the decision-making of FDA officials.
However, there is still a lot of work to be done to address the long history of malfeasance and inappropriate relationships between the FDA and the pharmaceutical industry. The Aduhelm controversy is just the latest example of why this is so important. If the FDA is not able to regulate the pharmaceutical industry effectively, patients will continue to be put at risk, and drugs that are not actually effective or safe will continue to be approved.
There are several things that can be done to address these issues. First, the FDA needs to be more transparent about its relationship with the pharmaceutical industry. This means disclosing all financial conflicts of interest and taking steps to ensure that FDA officials are not unduly influenced by the industry.
Second, the FDA needs to be more rigorous in its review process for new drugs. The FDA should not be approving drugs that have not been shown to be safe and effective, and it should be holding pharmaceutical companies accountable for any manipulation of clinical trial data.
Third, the FDA needs to be more independent from the pharmaceutical industry. This means reducing its dependence on user fees paid by the industry and ensuring that FDA officials are not unduly influenced by the industry.
In conclusion, the controversy surrounding Aduhelm has brought to light the long history of malfeasance and inappropriate relationships between the FDA and the pharmaceutical industry. It is important that these issues are addressed in order to ensure that the FDA is able to regulate the industry effectively and ensure that drugs are safe and effective for patients. The congressional investigation into the FDA’s approval process is a step in the right direction, but more needs to be done to ensure that the FDA is truly independent from the pharmaceutical industry and is able to make decisions that are in the best interests of patients.
Follow, Subscribe, & SHARE:
1. Telegram: https://t.me/TheTruthAboutCancer_Vaccines
3. GETTR: https://gettr.com/user/cancertruth
4. TruthSocial: https://truthsocial.com/@TheTruthAboutCancer
6. Bitchute: https://www.bitchute.com/channel/vX3lcHH4Dvp0/
8. Brighteon: https://www.brighteon.com/channels/thetruthaboutcancer